SCM
AMLX icon

Silverarc Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Silverarc Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,000
Closed -$56.8K – 72
2024
Q1 		$56.8K Buy
+20,000
New +$262K 0.02% 75

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Silverarc Capital Management's AMLX Position: Q1 2026 in Review

Silverarc Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 506,242 shares — an estimated $6.12M sold.

Silverarc Capital Management first reported a position in AMLX in Q1 2022 and held it in 4 quarters. The position peaked at $9.51M in Q3 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Silverarc Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 506,242 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $6.12M.
  • Silverarc Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Silverarc Capital Management's Amylyx Pharmaceuticals position peaked at $9.51M in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.